Worth reading
41Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
56
¥ million (year-on-year decrease in revenue)Wording
Conditional
How definitive the wording is.Contents of this document
Supplementary materials to the earnings reportFirst quarter of the fiscal year ending March 20278 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥935 million-5.6%
Operating profit¥-238 million
Ordinary income¥-237 million
Net income¥-274 million net income attributable to owners of the parent
Gross Profit Margin25.1 % and year-on-year percentage-point change
Results for the three months of the current quarter
Net Sales
¥935 million
Operating profit
¥-238 million
Ordinary income
¥-237 million
Net income
¥-274 million net income attributable to owners of the parent
Full-year earnings forecast
Net Sales
¥60 million
Operating profit
¥4 million
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Within the range assumed at the beginning of the fiscal year (regarding factors behind the decline in profit)Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Reaction to large projects recorded in the same quarter of the previous yearDetailsFactor behind the decline in revenue from data utilization services
- Decline in RevenueDetailsFactor behind the widening operating loss
- Wage increasesDetailsFactor behind the widening operating loss; amount not disclosed
- Higher Depreciation ExpenseDetailsFactor behind the widening operating loss; amount not disclosed
New initiatives
- Rollout of AI products combining proprietary data with AI
- Joint proof-of-concept projects with partners in the Global South, followed by phased commercialization
- Expansion into adjacent areas, including nursing care and frailty prevention
- Joint development of real-world data (RWD) and AI
- Development and provision of an AI-driven RWD analytics platform
Key KPIsA metric the company considers important as a management benchmark.
- Number of companies using data utilization services89 companiesYear on year against the same period last year+31.0%
- Number of pharmaceutical and other companies using the services38 companies
- Transaction value per customer among the top 20 customers7.5 % increaseYear on year against the same period last year+7.5%
- Number of orders for fiscal 2026 from municipal national health insurance programs419 Engagements
- Number of orders for fiscal 2026 from other customers135 Engagements
- Number of municipalities served700 Local government
- Health Big Data1,900 More than 10,000 people
- Renewal rate in the following year80 Approximately %
Unit price and quantity metricsThese figures show sales broken down by price and volume.
- Number of customers89 companiesYear on year against the same period last year+31.0%
- Transaction value per customer among the top 20 pharmaceutical and other companies7.5 % increaseYear on year against the same period last year+7.5%
Segment results
- Data health-related servicesNet Sales¥774 millionPrior-year period¥748 millionYear-on-year change in amount¥25 million
- Data utilization servicesNet Sales¥137 millionPrior-year period¥216 millionYear-on-year change-37
- OtherNet Sales¥25 millionPrior-year period¥27 millionYear-on-year change in amount¥-2 million
Medium-term management plan targets
Target fiscal yearFY2030
Operating profit margin15% or higher
AI-related revenue ratio20% or higher
Market Size / Share
Maintains a high share of the municipal national health insurance market (specific share figures not disclosed)| Item | Details |
|---|---|
| Document type | Supplementary materials to the earnings report |
| Fiscal Period Covered | First quarter of the fiscal year ending March 2027 |
| Net Sales | ¥935 million (YoY -5.6%) |
| Operating profit | ¥-238 million |
| Ordinary income | ¥-237 million |
| Net income | ¥-274 million (net income attributable to owners of the parent) |
| Gross Profit Margin | 25.1 % and year-on-year percentage-point change |
| Results for the three months of the current quarter | Net Sales ¥935 million / Operating profit ¥-238 million / Ordinary income ¥-237 million / Net income ¥-274 million (net income attributable to owners of the parent) |
| Full-year earnings forecast | Net Sales ¥60 million / Operating profit ¥4 million |
| Self-assessment against the plan | Within the range assumed at the beginning of the fiscal year (regarding factors behind the decline in profit) |
| Segment results | Segment Data health-related services / Net Sales ¥774 million / Prior-year period ¥748 million / Year-on-year change in amount ¥25 million / Profit Not disclosed, Segment Data utilization services / Net Sales ¥137 million / Prior-year period ¥216 million / Year-on-year change -37 % / Profit Not disclosed, Segment Other / Net Sales ¥25 million / Prior-year period ¥27 million / Year-on-year change in amount ¥-2 million / Profit Not disclosed |
| Breakdown of Factors Affecting the Change | Item Reaction to large projects recorded in the same quarter of the previous year / Details Factor behind the decline in revenue from data utilization services, Item Decline in Revenue / Details Factor behind the widening operating loss, Item Wage increases / Details Factor behind the widening operating loss; amount not disclosed, Item Higher Depreciation Expense / Details Factor behind the widening operating loss; amount not disclosed |
| Key KPIs | Number of companies using data utilization services 89 companies, Number of pharmaceutical and other companies using the services 38 companies, Transaction value per customer among the top 20 customers 7.5 % increase, Number of orders for fiscal 2026 from municipal national health insurance programs 419 Engagements, Number of orders for fiscal 2026 from other customers 135 Engagements, Number of municipalities served 700 Local government, Health Big Data 1,900 More than 10,000 people, Renewal rate in the following year 80 Approximately % |
| Unit price and quantity metrics | Number of customers 89 companies, Transaction value per customer among the top 20 pharmaceutical and other companies 7.5 % increase |
| Medium-term management plan targets | Target fiscal year FY2030 / Operating profit margin 15% or higher / AI-related revenue ratio 20% or higher |
| Market Size / Share | Maintains a high share of the municipal national health insurance market (specific share figures not disclosed) |
| New initiatives | Rollout of AI products combining proprietary data with AI, Joint proof-of-concept projects with partners in the Global South, followed by phased commercialization, Expansion into adjacent areas, including nursing care and frailty prevention, Joint development of real-world data (RWD) and AI, Development and provision of an AI-driven RWD analytics platform |
Items this document does not state (14)
Operating profit marginSelling, general and administrative expensesProgress against full-year forecastNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The decline in revenue was due to the reaction to the large projects recorded in the same quarter of the previous year. The widening operating loss was attributed to the decline in revenue, as well as higher wages and depreciation expenses. The company states that all of these factors were within the range assumed at the beginning of the fiscal year.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.